Holen Sie sich die Stockscreener-App
3.45
29.21%
0.78
Handel nachbörslich:
3.40
-0.05
-1.45%
Schlusskurs vom Vortag:
$2.67
Offen:
$2.77
24-Stunden-Volumen:
2.99M
Relative Volume:
7.21
Marktkapitalisierung:
$192.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.39M
KGV:
-4.1071
EPS:
-0.84
Netto-Cashflow:
$-18.45M
1W Leistung:
+78.76%
1M Leistung:
+96.02%
6M Leistung:
+210.81%
1J Leistung:
+70.79%
1-Tages-Spanne:
$2.7601
$3.58
1-Wochen-Bereich:
$1.92
$3.58
52-Wochen-Spanne:
$0.7203
$3.58
Quince Therapeutics Inc Stock (QNCX) Company Profile
Firmenname
Quince Therapeutics Inc
Sektor
Branche
Telefon
415-910-5717
Adresse
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Vergleichen Sie QNCX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
3.45 | 148.67M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Eingeleitet | Oppenheimer | Outperform |
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Consensus Target Price from Analysts - Defense World
Quince Therapeutics, Inc. (QNCX) 18.8% in Intraday Trading: Surge Amid Upcoming Investor Events - Stocks Telegraph
Quince Therapeutics Stock Rockets 59% With 7-Day Winning Streak - Trefis
Adversity is less terrifying than hope: Quince Therapeutics Inc (QNCX) - Setenews
Quince Therapeutics (QNCX) joins investor events as Phase 3 NEAT data in 2026 - Stock Titan
Is Quince Therapeutics Inc. stock a dividend growth opportunity2025 Historical Comparison & Growth Oriented Trade Recommendations - newser.com
A new trading data show Quince Therapeutics Inc (QNCX) is showing positive returns. - Setenews
Can Quince Therapeutics Inc. stock weather global recessionWeekly Stock Recap & Detailed Earnings Play Alerts - newser.com
Sentiment analysis tools applied to Quince Therapeutics Inc.Quarterly Portfolio Report & Weekly High Conviction Ideas - newser.com
How analysts rate Quince Therapeutics Inc. stock todayM&A Rumor & Low Risk Entry Point Tips - newser.com
Statistical indicators supporting Quince Therapeutics Inc.’s strengthGDP Growth & Technical Entry and Exit Alerts - newser.com
Can Quince Therapeutics Inc. stock double in next 5 yearsMarket Trend Review & Weekly Hot Stock Watchlists - newser.com
Combining machine learning predictions for Quince Therapeutics Inc.Global Markets & Daily Chart Pattern Signal Reports - newser.com
Is Quince Therapeutics Inc. stock a good choice for value investorsMarket Risk Summary & Risk Managed Investment Strategies - newser.com
How interest rate cuts could boost Quince Therapeutics Inc. stockShort Setup & Daily Oversold Stock Bounce Ideas - newser.com
What indicators show strength in Quince Therapeutics Inc.July 2025 Levels & Weekly High Return Opportunities - newser.com
Is Quince Therapeutics Inc. stock oversold or undervaluedJuly 2025 Price Swings & Reliable Breakout Forecasts - newser.com
Quince Therapeutics Reports Q3 2025 Financial Results - MSN
Is Quince Therapeutics Inc. stock ready for a breakout2025 Macro Impact & Daily Volume Surge Signals - newser.com
Is Quince Therapeutics Inc. stock positioned for digital transformationEarnings Summary Report & AI Forecast Swing Trade Picks - newser.com
Oppenheimer Sticks to Its Buy Rating for Quince Therapeutics (QNCX) - The Globe and Mail
Why retail investors favor Quince Therapeutics Inc. stockIndex Update & Stock Portfolio Risk Management - newser.com
Finanzdaten der Quince Therapeutics Inc-Aktie (QNCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):